Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Status:
Terminated
Trial end date:
2018-06-28
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well vismodegib works in treating patients with chronic
graft-versus-host disease that did not respond to previous steroid treatment. Chronic
graft-versus-host disease can cause a build-up of scar tissue under the skin and lead to
symptoms such as sclerodermatous skin changes, dry mouth, dry eye, narrowing of the
esophagus, or vaginal graft-versus-host disease. Vismodegib may work against the build-up of
scar tissue and be a better treatment for chronic graft-versus-host disease caused by a
hematopoietic stem cell transplant.